Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing “where” by “what”…

Abstract

ABSTRACT. Neurodegenerative dementias have been described based on their phenotype, in relation to selective degeneration occurring in a particular neuroanatomical system. More recently however, the term proteinopathy has been introduced to describe diseases in which one or more altered proteins can be detected. Neurodegenerative diseases can be produced by more than one abnormal protein and each proteinopathy can determine different clinical phenotypes. Specific biomarkers have now been linked to certain molecular pathologies in live patients. In 2016, a new biomarker-based classification, currently only approved for research in Alzheimer’s disease, was introduced. It is based on the evaluation three biomarkers: amyloid (A) detected on amyloid-PET or amyloid- beta 42 assay in CSF; tau (T) measured in CSF as phosphorylated tau or on tau PET imaging; and neuronal injury/neurodegeneration (N), detected by total T-tau in CSF, FDG PET hypometabolism and on MRI brain scan. Results of clinical research using the ATN biomarkers at FLENI, a Neurological Institute in Buenos Aires, Argentina have, since 2011, contributed to ongoing efforts to move away from the concept of neurodegenerative dementias and more towards one of cognitive proteinopathies. Today, clinical diagnosis in dementia can only tell us “where” abnormal tissue is found but not “what” molecular mechanisms are involved.

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders

“…Their early identification is crucial, but still today, it is challenging. CSF biomarkers represent precious tools for assessing neurodegenerative disorders providing in vivo information on the underlying pathology [ 21 , 22 , 23 , 24 ]. Specifically, CSF is an ideal biofluid due to its proximity to the brain parenchyma, the moderately low cost in comparison to positron emission tomography imaging, and the safety of lumbar puncture.…”

Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer’s Disease

“…Neurodegenerative diseases are an important health burden and their early identification is crucial, but this is still challenging today. CSF biomarkers represent precious tools for assessing neurodegenerative disorders, providing in vivo information on the underlying pathology [ 23 , 24 , 25 , 26 , 27 ]. Specifically, CSF is an ideal biofluid due to its proximity to the brain parenchyma, the lower intrinsic protease activity than blood, the moderately low cost in comparison to positron emission tomography (PET) imaging and the safety of lumbar puncture.…”

Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast‐Developing Field

“…The cognitive proteinopathy field 27 has predominantly focused on imaging targets involved in the neurodegenerative process. Tau PET imaging is undoubtedly the best choice for the differential diagnosis of PD/DLB and other forms of atypical parkinsonism (see Fig 3B ).…”